109063-57-2

Upstream product

• 108-24-7 acetic anhydride 
• 17342-08-4 (S)-Pyroglutaminol 
• 17342-08-4 (S)-5-Hydroxymethyl-4,5-dihydro-3H-pyrrol-2-ol 

Downstream Products

• 1308719-74-5 1-((2S)-(1-[4-(methoxycarbonyl)benzyl]-5-oxotetrahydro-1H-pyrrol-2-yl)methyl)-1H-imidazole-5-carboxylic acid 
• 1308719-66-5 1-[[1-[[4-(methoxycarbonyl)phenyl]methyl]-5-oxo-(2S)-pyrrolidinyl]methyl]-1H-imidazole-5-carboxylic acid phenylmethyl ester 
• 1308719-79-0 1-[[1-[[4-(methoxycarbonyl)phenyl]methyl]-5-oxo-(2S)-pyrrolidinyl]methyl]-1H-imidazole-4-carboxylic acid phenylmethyl ester 
• 1308719-61-0 4-[[(2S)-(1H-imidazol-1-ylmethyl)-5-oxo-1-pyrrolidinyl]methyl]benzoic acid methyl ester 
• 1308719-58-5 4-[[(2S)-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-5-oxo-1-pyrrolidinyl]methyl]benzoic acid methyl ester 
• 1308719-54-1 4-[[(2S)-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]methyl]benzoic acid methyl ester 
• 1308719-30-3 C₂₂H₂₃NO₅ 
• 1308719-32-5 4-(bromomethyl)benzoic acid [5-oxo-1-[[4-[(phenylmethoxy)carbonyl]phenyl]methyl]-(2S)-pyrrolidinyl]methyl ester 
• 1308719-51-8 4-[[(2S)-[(acetyloxy)methyl]-5-oxo-1-pyrrolidinyl]methyl]benzoic acid methyl ester 
• 109021-53-6 cis-N-trifluoromethyl-5-n-heptyl-(S)-2-tosyloxymethylpyrrolidine 
• 109021-53-6 trans-N-trifluoromethyl-5-n-heptyl-(S)-2-tosyloxymethylpyrrolidine 
• 109063-59-4 cis-N-benzyl-5-n-heptyl-(S)-2-hydroxymethylpyrrolidine 
• 109021-49-0 trans-N-benzyl-5-n-heptyl-(S)-2-hydroxymethylpyrrolidine 
• 109021-50-3 N-tosyl-5-n-heptyl-(S)-2-tosyloxymethylpyrrolidine 

Relevant academic research and scientific papers

Synthesis, in silico docking experiments of new 2-pyrrolidinone derivatives and study of their anti-inflammatory activity

A new class of 2-pyrrolidinone derivatives was designed, synthesized, and tested for their antioxidant and anti-inflammatory activities. The compounds were evaluated for their inhibitory activity against LOX. The most potent among them, 14d [IC50 0.08 (±0.005) mM], and 14e [IC50 0.0705 (±0.003) mM], were also tested in vivo. The compound 14d induced equipotent inhibition against rat paw edema, which is very close to the effect produced by the commonly used standard, namely indomethacin (47%). The LOX inhibitory activity of the compound 14e proceeds in parallel to the % inhibitory value of lipid peroxidation meaning that this LOX inhibitory activity is supported by the lipid peroxidation inhibition. The molecular features that govern their bioactivity were explored through in silico docking experiments. The results showed that acidic moieties must be placed in certain distance and orientation in the active site of LOX enzyme in order to productively exhibit inhibitory activity. In addition, the 2-pyrrolidinone template significantly contributes in the inhibitory properties of the new compounds.

A new synthesis of ant venom alkaloid: (3S,5R,8S)-3-heptyl-5-methylpyrrolizidine

A highly enantioselective synthesis of (3S,5R,8S)-3-heptyl-5-methylpyrrolizidine is described by using (S)-pyroglutamic acid as starting material.

Enantioselective syntheses of Monomorium minutum ant venom alkaloids: (5R)-2-(5-Hexenyl)-5-nonyl-3,4-dihydro-2H-pyrrole and (2R,5R)-2-(5-Hexenyl)-5-nonpyrrolidine from (S)-pyroglutamic acid

We describe enantioselective syntheses of 2,5-disubstituted pyrroline and pyrrolidine with unsaturated radical, starting from (S)-pyroglutamic acid

Alkaloids Asymmetric Synthesis from (S)-Pyroglutamic Acid. II. Attempted asymmetric Total Synthesis of Trans-5-ethyl-2-n-heptylpyrrolidine

From the readily avaiable (S)-pyroglutamic acid 1 the asymmetric synthesis of trans and cis 5-n-heptyl-2-(S)-hydroxymethylpyrrolidines 7 , some derivatives and transformations are described.